Literature DB >> 30227946

Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.

Jian-Kang Jiang1, Xiuli Huang2, Khalida Shamim2, Paresma R Patel2, Arthur Lee2, Amy Q Wang2, Kimloan Nguyen2, Gregory Tawa2, Gregory D Cuny3, Paul B Yu4, Wei Zheng2, Xin Xu2, Philip Sanderson2, Wenwei Huang5.   

Abstract

The pyrazolo[1,5-a]pyrimidine LDN-193189 is a potent inhibitor of activin receptor-like kinase 2 (ALK2) but is nonselective for highly homologous ALK3 and shows only modest kinome selectivity. Herein, we describe the discovery of a novel series of potent and selective ALK2 inhibitors by replacing the quinolinyl with a 4-(sulfamoyl)naphthyl, yielding ALK2 inhibitors that exhibit not only excellent discrimination versus ALK3 but also high kinome selectivity. In addition, the optimized compound 23 demonstrates good ADME and in vivo pharmacokinetic properties.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ALK2; FOP; LDN-193189; Pyrazolo[1,5-a]pyrimidine; Sulfamoylnaphthyl

Mesh:

Substances:

Year:  2018        PMID: 30227946      PMCID: PMC6218249          DOI: 10.1016/j.bmcl.2018.09.006

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  24 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

3.  Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.

Authors:  Ivelina Gueorguieva; Ann L Cleverly; Anja Stauber; N Sada Pillay; Jordi A Rodon; Colin P Miles; Jonathan M Yingling; Michael M Lahn
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

4.  Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.

Authors:  Salin A Chakkalakal; Kenta Uchibe; Michael R Convente; Deyu Zhang; Aris N Economides; Frederick S Kaplan; Maurizio Pacifici; Masahiro Iwamoto; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2016-03-12       Impact factor: 6.741

Review 5.  A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.

Authors:  Frederick S Kaplan; David L Glaser; Robert J Pignolo; Eileen M Shore
Journal:  Expert Opin Biol Ther       Date:  2007-05       Impact factor: 4.388

Review 6.  Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Bone       Date:  2008-05-28       Impact factor: 4.398

7.  Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.

Authors:  Frederick S Kaplan; Leonid Zeitlin; Stephen P Dunn; Shira Benor; David Hagin; Mona Al Mukaddam; Robert J Pignolo
Journal:  Bone       Date:  2017-12-11       Impact factor: 4.398

8.  Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.

Authors:  Darren W Engers; Audrey Y Frist; Craig W Lindsley; Charles C Hong; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2013-04-11       Impact factor: 2.823

Review 9.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

Review 10.  Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.

Authors:  Eleanor Williams; Alex N Bullock
Journal:  Bone       Date:  2017-09-12       Impact factor: 4.398

View more
  5 in total

1.  Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.

Authors:  Darren W Engers; Sean R Bollinger; Andrew S Felts; Anish K Vadukoot; Charles H Williams; Anna L Blobaum; Craig W Lindsley; Charles C Hong; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2020-07-17       Impact factor: 2.823

2.  Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.

Authors:  Deeba Ensan; David Smil; Carlos A Zepeda-Velázquez; Dimitrios Panagopoulos; Jong Fu Wong; Eleanor P Williams; Roslin Adamson; Alex N Bullock; Taira Kiyota; Ahmed Aman; Owen G Roberts; Aled M Edwards; Jeff A O'Meara; Methvin B Isaac; Rima Al-Awar
Journal:  J Med Chem       Date:  2020-05-05       Impact factor: 7.446

3.  Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Authors:  Elias C Padilha; Jianyao Wang; Ed Kerns; Arthur Lee; Wenwei Huang; Jian-Kang Jiang; John McKew; Abdul Mutlib; Rosangela G Peccinini; Paul B Yu; Philip Sanderson; Xin Xu
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

4.  An efficient and targeted synthetic approach towards new highly substituted 6-amino-pyrazolo[1,5-a]pyrimidines with α-glucosidase inhibitory activity.

Authors:  Fariba Peytam; Mehdi Adib; Reihaneh Shourgeshty; Loghman Firoozpour; Mahmoud Rahmanian-Jazi; Mehdi Jahani; Setareh Moghimi; Kouros Divsalar; Mohammad Ali Faramarzi; Somayeh Mojtabavi; Fatemeh Safari; Mohammad Mahdavi; Alireza Foroumadi
Journal:  Sci Rep       Date:  2020-02-13       Impact factor: 4.379

5.  Temperature-modulated selective C(sp3)-H or C(sp2)-H arylation through palladium catalysis.

Authors:  Thirupathi Gogula; Jinquan Zhang; Madhava Reddy Lonka; Shuaizhong Zhang; Hongbin Zou
Journal:  Chem Sci       Date:  2020-09-24       Impact factor: 9.825

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.